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Introduction:We aimed to assess episodic memory in genetic frontotemporal demen-
tia (FTD) with the Free and Cued Selective Reminding Test (FCSRT).
Methods: The FCSRT was administered in 417 presymptomatic and symptomatic
mutation carriers (181 chromosome 9 open reading frame 72 [C9orf72], 163 progran-
ulin [GRN], and73microtubule-associatedprotein tau [MAPT]) and290controls.Group
differences and correlations with other neuropsychological tests were examined. We
performed voxel-based morphometry to investigate the underlying neural substrates
of the FCSRT.
Results:All symptomaticmutation carrier groups andpresymptomaticMAPTmutation
carriers performed significantly worse on all FCSRT scores compared to controls. In
the presymptomatic C9orf72 group, deficits were found on all scores except for the
delayed total recall task,while nodeficitswere found in presymptomaticGRNmutation
carriers. Performance on the FCSRT correlated with executive function, particularly in
C9orf72mutation carriers, but also withmemory and naming tasks in theMAPT group.
FCSRTperformance also correlatedwith graymatter volumes of frontal, temporal, and
subcortical regions in C9orf72 and GRN, but mainly temporal areas inMAPTmutation
carriers.
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Discussion: The FCSRT detects presymptomatic deficits in C9orf72- and MAPT-
associated FTD and provides important insight into the underlying cause of memory
impairment in different forms of FTD.
KEYWORDS
cognition, episodic memory, executive function, frontal lobe, frontotemporal dementia, genetic
disorders, neuropsychology, temporal lobe, voxel-basedmorphometry
1 BACKGROUND
Memory deficits are often considered indicative of the onset of
Alzheimer’s disease (AD), but an increasing number of studies have
reported episodic memory impairment in the frontotemporal demen-
tia (FTD)1,2 spectrum as well, even at initial presentation.3 There is
ongoing discussion on what underlies episodic memory impairment in
FTD, with some studies suggesting that it may be a consequence of
poor organization and a lack of efficient learning and retrieval strate-
gies (i.e., due to a dysexecutive syndrome caused by [pre]frontal corti-
cal damage) and others suggesting that it is due to “true” consolidation
problems, as is the case in AD, as a result of damage to mesiotemporal,
including hippocampal, structures of the brain.4–7
Delineating the contribution of executive/frontal and mem-
ory/hippocampal functioning tomemory impairment can be performed
using memory tests that separate learning, storage, and retrieval pro-
cesses. The Free and Cued Selective Reminding Test (FCSRT) was
designed specifically for this purpose.8 The FCSRT uses semantic cues
to, first, test if words were effectively encoded, and, second, facili-
tate subsequent cued recall of words that were not spontaneously
retrieved during free recall. Specifically, the performance on cued
recall is assumed to provide ameasure of “true”memory consolidation,
while performance on free recall also relies on executive functioning as
it requires people to apply an effective learning and retrieval strategy.5
Some studies have shown that this paradigm is effective in differen-
tiating behavioral variant FTD (bvFTD) from AD,6,7,9–12 while others
have failed to show this distinction, or showed that the FTD sample
could be split, with approximately half of the patients performing as
poorly as patients with AD and the other half performing similarly
to healthy controls.6,11,13 Indeed, several neuroimaging studies have
shown differences in temporal lobe involvement between amnesic and
non-amnesic patients with FTD,4,11,14,15 underlining the pathological
and clinical heterogeneity of this disease spectrum.
In approximately 30% of cases, FTD is caused by genetic mutations
in progranulin (GRN), microtubule-associated protein tau (MAPT), and
chromosome 9 open reading frame 72 (C9orf72).16 GRN mutations
often lead to an asymmetrical pattern of atrophy in the frontal, tempo-
ral, and parietal lobes, whereasMAPTmutations show localized tempo-
ral lobe involvement.17 Theatrophyassociatedwith theC9orf72 repeat
expansion is rather diffuse with degeneration of the frontal and tem-
poral cortices but also involvement of the subcortical and cerebellar
regions.18 Memory impairment has been described in GRN19,20 and
C9orf7218 mutation carriers as a prominent symptom of later disease
stages, whereas in MAPT mutation carriers memory decline has been
previously described in the presymptomatic stage.21 A recent study
has shown that patients with aGRNmutation orC9orf72 repeat expan-
sion were impaired on immediate recall, whereasMAPTmutation car-
riers were impaired on both immediate and delayed recall. According
to the classic view, this suggests a “pure” memory impairment due to
temporal involvement in MAPT, whereas the immediate recall impair-
ment in C9orf72 and GRN mutation carriers are potentially a conse-
quence of prefrontal and thus executive dysfunction, with relatively
spared delayed recall performance.22 However, systematic investiga-
tions of episodicmemory performance using paradigms that can differ-
entiate between primary executive versus true amnestic mechanisms
have not been performed in detail in genetic FTD, and in particular, not
in the presymptomatic stage. Clinical trials targeting specific patholo-
gies are currently being developed and implemented for both early
symptomatic and presymptomatic mutation carriers and it is impor-
tant to identify gene-specific sensitive outcomemeasures for signaling
disease onset, tracking disease progression, and measuring potential
treatment effects at an early disease stage.
The aim of this study is therefore to assess memory performance in
a large cohort of genetic FTD families by means of the FCSRT and cor-
relate performance with gray matter volume using voxel-based mor-
phometry. We compared both presymptomatic individuals and those
with symptomatic FTD with pathogenic mutations in MAPT, GRN, or
C9orf72 to a control group of mutation-negative individuals from the
same families. Data was collected within the Genetic Frontotemporal
Dementia Initiative (GENFI), an international genetic FTDcohort study
aimed at developing novel markers of disease onset and progression.23
2 METHODS
2.1 Participants
Baseline data was included from the fifth GENFI data freeze in
whichparticipants fromconfirmedgenetic FTD familieswere recruited
between January 30, 2012 andMay 31, 2019 in 24 centers. The FCSRT
was administered in a total of 417mutation carriers (181 C9orf72, 163
GRN, and 73MAPT) and 290 mutation negative controls. Of the muta-
tion carrier group 96 participants were symptomatic, fulfilling diag-
nostic criteria for bvFTD1 (44 C9orf72, 19 GRN, 17MAPT), non-fluent
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HIGHLIGHTS
∙ The Free and Cued Selective Reminding Test (FCSRT)
is able to detect presymptomatic episodic memory
impairment in both chromosome 9 open reading frame
72 (C9orf72)- and microtubule-associated protein tau
[MAPT]-associated frontotemporal dementia (FTD).
∙ Deficits in presymptomatic MAPT mutation carriers are
likely to be due to “true” episodic memory deficits.
∙ Impaired memory performance in progranulin (GRN)- and
C9orf72-associated FTD is likely to be mainly related to
executive dysfunction.
∙ FCSRT performance is associated with temporal lobe
regions in MAPT-associated FTD, with additional frontal
lobe involvement inGRN- and C9orf72-associated FTD.
∙ The FCSRT provides insight into the underlying cause of
memory impairment in FTD.
variant primary progressive aphasia (nfvPPA;2 1 C9orf72, 8 GRN), or
FTD with amyotrophic lateral sclerosis (FTD-ALS;24 4 C9orf72). The
presymptomatic mutation carrier group did not fulfill these diagnos-
tic criteria, had a Clinical Dementia Rating scale plus behavioral and
language domains from the National Alzheimer’s Coordinating Center
(NACC) FTLDmodule (CDR plus NACC FTLD) ≤0.525 and consisted of
129 C9orf72 repeat expansion, 136 GRN, and 56MAPTmutation carri-
ers. There were 352 mutation carriers with an FCSRT at baseline that
also had a structural (T1-weighted) magnetic resonance imaging (MRI)
brain scan (148 C9orf72, 139GRN, and 65MAPTmutation carriers). All
GENFI sites had local ethical approval for the study and all participants
gave written informed consent. The study was in accordance with the
Declaration of Helsinki.
2.2 Procedure
We administered the Mini-Mental State Examination (MMSE)26 to
measure global cognitive functioning and determined clinical status
by means of a structured clinical interview, including the CDR plus
NACC FTLD,25 with the participant and a knowledgable informant.
The FCSRT was administered as part of the GENFI neuropsycho-
logical test battery.23 From this test battery we also collected data
on visual episodic memory (Benson figure recall), language (30-item
Boston Naming Test [BNT]27 and category fluency27), and executive
function tests (Trail Making Test part B [TMT-B28] and the Delis–
Kaplan Executive Function System Color-Word Interference Test [D-
KEFS Color-Word] card III29) to correlate with FCSRT performance.
The test battery was administered in the same order to all participants
and no semantic tests were administered during the delay phase of the
FCSRT.
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using PubMed. While episodic memory functioning has
not been investigated systematically in (presymptomatic)
genetic frontotemporal dementia (FTD), there have been
several publications describing neuropsychological test
results, including memory, in genetic FTD. Relevant cita-
tions are cited.
2. Interpretation: Our findings demonstrate that memory
deficits are an integral part of the clinical spectrum in
microtubule-associated protein tau (MAPT) mutation car-
riers, whereas lower memory test scores in chromosome
9 open reading frame 72 (C9orf72) repeat expansion and
progranulin (GRN) mutation carriers are more likely to be
the consequence of executive dysfunction. These results
are consistentwith previous studies showing degradation
of memory-related temporal areas in MAPT-associated
FTD, and more executive function-related frontal areas
being implicated inGRN- and C9orf72-associated FTD.
3. Future directions: Results from this study provide new
insights andguidance for additional studies, such as inves-
tigating longitudinal trajectories of the FCSRT in genetic
FTD as well as investigating the sensitivity of the FCSRT
as a potential outcome measure for upcoming clinical
trials.
2.3 Free and Cued Selective Reminding Test
(FCSRT)
The FCSRT consists of 16 words to be learned, presented four at a
time on successive cards. Each word belongs to a different semantic
category (e.g., herring in the semantic category “fish”). The first pre-
sentation is aimed at inducing semantic encoding, for which subjects
are asked to read aloud the word corresponding to a specific semantic
category (e.g., “What is the name of the fish?”). After all four items
are named, the card is removed and the test administrator asks for
immediate recall of the four words in response to the semantic cue.
This procedure of encoding is repeated a maximum of three times,
until the participant is able to recall all four words or has completed
the third round, after which the following card is administered and this
encoding process is then repeated for the second, third, and fourth
cards. Subsequently, three successive trials of free recall are admin-
istered, where participants are asked to remember as many of the 16
words as possible within two minutes. Each free recall trial is followed
by a selective semantic cuing of the words that are not spontaneously
recalled. After 20 to 30 minutes, a delayed free recall and then cued
recall of words not spontaneously recalled is administered. This results
in four scores to be analyzed: immediate free recall (max. score = 48),
immediate total recall (free+cued; max. score = 48), delayed free
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recall (max. score = 16), delayed total recall (delayed free+cued; max.
score = 16). The test was administered across the GENFI centers in
eight languages: English, Dutch, Swedish, Spanish, Italian, Portuguese,
German, and French.
2.4 Structural brain imaging and voxel-based
morphometry
Participants underwent volumetric T1-weighted MRI according to the
GENFI imaging protocol on a 3T scanner. Different scanners were
used across GENFI sites: Siemens Trio 3T (n = 105), Siemens Skyra
3T (n = 55), Siemens Prisma 3T (n = 57), and Philips Achieva 3T
(n = 101). All scans underwent extensive visual quality checke and
those with artifacts or incidental brain abnormalities unrelated to
FTD were excluded from analysis. Voxel-based morphometry (VBM)
was performed using Statistical Parametric Mapping (SPM) 12 soft-
ware, version 6225 (www.fil.ion.ucl.ac.uk/spm) running under Matlab
R2018a (Mathworks). T1-weighted images were normalized and seg-
mented into gray matter (GM), white matter (WM), and cerebrospinal
fluid (CSF) probability maps, using standard procedures and the fast
diffeomorphic image registration algorithm (DARTEL).30 GM segmen-
tations were affine transformed into the Montreal Neurological Insti-
tute (MNI) space, modulated and smoothed using a Gaussian kernel
with 6 mm full width at half maximum. Finally, a mask was applied as
reported in Ridgway et al.31 All segmentations were visually checked
at each stage. Total intracranial volume (TIV; i.e., GM+WM+CSF) was
calculated using SPM12.32
2.5 Statistical analysis
Statistical analyseswereperformedusing Stata version14 (StataCorp).
The significance level was set at P < 0.05 (two-tailed) across all com-
parisons. We compared demographic data between groups with lin-
ear regression models except for sex, which was compared using a chi-
square test.
Performance in controls was assessed by calculating the cumula-
tive frequency of test scores (and therefore percentile scores) as well
as investigating the effect of age (Spearman rank correlation), years
of education (Spearman rank correlation), sex (Mann–Whitney U test),
and the language inwhich the testwas administered (Kruskal–Wallis H
test).
Mean differences on each FCSRT score between groups were ana-
lyzed with mixed models correcting for age, years of education, sex,
language inwhich the testwas administered, and family clusteringwith
95%bias-correctedbootstrappedconfidence intervalswith1000s rep-
etitions (due to non-normality).
Spearman rankcorrelationswereused to investigate theassociation
of each FCSRT test score with the Benson figure recall, BNT, category
fluency, TMT-B, and D-KEFS Color-Word tasks.
The relationship of performance on each FCSRT test score with GM
density was explored in each mutation carrier (presymptomatic and
symptomatic combined) group within the VBM analysis using multiple
regression models. Age, sex, scanner, and TIV were included as covari-




Demographic data are shown in Table 1. There was a significant dif-
ference in sex between the groups, X2(6, N = 707) = 16.8, P = 0.010,
with more females in the presymptomatic and control group and more
males in the symptomatic groups. Symptomatic groups were signifi-
cantly older than controls and presymptomatic groups (all P < 0.001).
In addition, presymptomatic MAPT mutation carriers were signifi-
cantly younger than controls (P < 0.001), presymptomatic C9orf72
(P = 0.009), and GRN mutation carriers (P = 0.001). Symptomatic
C9orf72 and GRN mutation carriers had significantly lower years of
education than controls and presymptomatic C9orf72, GRN, andMAPT
mutation carriers (all P < 0.013). All symptomatic mutation carri-
ers performed significantly lower on the MMSE and had higher CDR
plus NACC FTLD global scores than controls and presymptomatic
C9orf72, GRN, and MAPT mutation carriers (all P < 0.005). In addi-
tion, symptomaticGRNmutation carriers had lowerMMSE scores than
symptomatic C9orf72 and MAPT mutation carriers (both P < 0.003)
and symptomatic C9orf72 mutation carriers had higher CDR plus
NACC FTLD global scores than symptomatic MAPT mutation carriers
(P= 0.028).
3.2 Normative data in the control population
Cumulative frequencies (Table A.1), percentile scores (Table A.2), and
mean score stratified by age group and sex (Table A.3) for mutation
negative controls can be found in the supporting information. Fifthper-
centile cut-off scores were 19 (immediate free), 40 (immediate total),
7 (delayed free), and 13 (delayed total) for each of the FCSRT scores
(Table A.2). There was a weak negative correlation with age (r between
–0.14 and –0.36) and a weak positive correlation with years of edu-
cation (r between 0.16 and 0.22) for each FCSRT score. Females per-
formed better than males on all parts of the FCSRT: immediate free
recall (z = 3.6, P < 0.001), immediate total recall (z = 2.6, P = 0.010),
delayed free recall (z= 4.4, P< 0.001), and delayed total recall (z= 3.1,
P = 0.002). There was also a significant effect of language on FCSRT
immediate free recall (H[7] = 24.3, P = 0.001), immediate total recall
(H[7]= 26.6, P< 0.001), and delayed free recall (H[7]= 25.9, P< 0.001)
but not delayed total recall (H[7]= 11.3, P= 0.127).
3.3 Group comparisons
All three symptomatic mutation carrier groups performed signifi-
cantly worse than controls on FCSRT immediate free recall, immedi-
ate total recall, delayed free recall, and delayed total recall (all P ≤
0.001; Tables 1 and 2). In addition, symptomatic GRN mutation car-
riers performed significantly worse on the FCSRT immediate total
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TABLE 1 Demographic information and FCSRT scores
C9orf72 GRN MAPT Controls
PS S PS S PS S –

















Sex ratio f:m 77:52 19:33 84:52 10:17 34:22 7:10 167:123
Education, y 14.4± 3.0 12.8± 3.3 14.7± 3.5 12.0± 3.5 14.5± 3.0 14.5± 3.9 14.6± 3.4
MMSE 29.0± 2.1 25.3± 3.9 28.7± 4.6 22.9± 6.8 29.5± 0.9 26.2± 3.1 29.3± 2.1
CDR plus NACC
FTLD global
0.1± 0.3 1.9± 1.0 0.1± 0.3 1.8± 0.9 0.1± 0.3 1.6± 0.9 0.1± 0.2
FCSRT immediate
free recall
28.8± 7.1 13.9± 8.4 31.2± 6.2 13.8± 12.5 31.6± 7.0 12.8± 10.2 31.5± 6.8
FCSRT immediate
total recall
44.4± 5.4 34.2± 13.1 45.8± 2.5 26.4± 17.5 45.3± 4.6 29.7± 13.1 45.7± 3.5
FCSRT delayed free
recall
11.0± 2.9 4.7± 3.5 11.9± 2.8 5.2± 4.7 12.0± 3.1 4.5± 4.7 12.0± 3.1
FCSRT delayed total
recall
15.3± 1.4 11.5± 4.7 15.5± 0.9 10.0± 6.3 15.3± 1.8 10.3± 4.9 15.5± 1.2
Note: All data are shown asmean± standard deviation.
Abbreviations: C9orf72, chromosome 9 open reading frame 72; CDR plus NACC FTLD global, Clinical Dementia Rating scale plus National Alzheimer’s Coor-
dinating Center Frontotemporal Lobar Degeneration global score; FCSRT, Free and Cued Selective Reminding Test; GRN, progranulin;MAPT, microtubule-
associated protein tau;MMSE,Mini-Mental State Examination; PS, presymptomatic; S, symptomatic.
score than symptomaticC9orf72 repeat expansion carriers (P= 0.047).
All symptomatic mutation carriers performed significantly worse than
presymptomatic mutation carriers (all P≤ 0.004).
Presymptomatic C9orf72 repeat expansion carriers performed sig-
nificantlyworseonFCSRT immediate free recall (P<0.001), immediate
total recall (P = 0.010), and delayed free recall (P < 0.001) than con-
trols, but not delayed total recall (p= 0.066) (Tables 1 and 2). Presymp-
tomatic MAPT mutation carriers had significantly lower FCSRT
immediate free recall (P = 0.005), immediate total recall (P = 0.002),
delayed free recall (P = 0.024), and delayed total recall (P = 0.011)
scores than controls. In addition, presymptomatic C9orf72 and MAPT
mutation carriers performed significantly worse than presymptomatic
GRNmutation carriers on all four FCSRT test scores (all P< 0.017).
3.4 Association with other neuropsychological
tests
Correlation coefficients for eachFCSRTscorewithotherneuropsycho-
logical tests by genetic group can be seen in Table 3. In the C9orf72
mutation carriers, the strongest correlations were with the D-KEFS
Color-Word task, particularly for the free recall scores, as well as cate-
gory fluency, with additional significant correlations with the BNT and
Benson figure recall, particularly in the symptomatic group. In theGRN
mutation carriers, the strongest correlations were with TMT-B as well
aswith theBenson figure recall andBNT for themajority of scores, par-
ticularly for the symptomatic group. In theMAPTmutation carriers the
strongest correlations were with the Benson figure recall (all signifi-
cant except delayed free recall in the symptomatic group), followed by
the BNT (for all scores), with no significant correlations with any of the
executive function tasks or category fluency in the symptomatic group.
3.5 Neuroanatomical correlates of performance
on the FCSRT
The VBM analyses revealed particular involvement of frontal
(orbitofrontal and dorsolateral prefrontal cortices), insula, tempo-
ral (particularly medial cortical areas), and parietal (angular gyrus
and precuneus) regions as well as the hippocampus in immediate free
recall score in GRN and C9orf72 mutation carriers, with additional
involvement of the thalamus and amygdala in the latter (Figure 1,
Table A.4 in supporting information). For the immediate total recall
score, a similar network was found in GRNmutation carriers as well as
the thalamus, but in C9orf72mutation carriers exclusively areas in the
medial temporal lobe including the hippocampus were found (Figure 2,
Table A.4). In MAPT mutation carriers, both immediate free and total
recall were correlated with atrophy of the medial temporal lobes
bilaterally (Figures 1 and 2, Table A.4). The overlap and differences in
statistical parametric maps between immediate free and total recall
can be seen in Figure A.1 in supporting information. For C9orf72
mutation carriers, similar findings were seen for delayed total recall
(Table A.4), although only frontal areas were associated with delayed
total recall for GRN mutation carriers. There were no associations
in GRN and MAPT mutation carriers for delayed free recall or in
MAPT mutation carriers for delayed total recall after FWE correction
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TABLE 2 The adjustedmean differences between groups and 95% confidence intervals for all four FCSRTmeasures
FCSRT immediate free recall
C9orf72 GRN MAPT
PS S PS S PS S
Controls –2.9 –12.5 0.4 –11.7 –2.4 –15.7
–4.1 –1.7 –14.8 –10.2 –0.8 1.6 –16.3 –7.1 –4.0 –0.7 –20.8 –10.6
C9orf72 PS -9.6 3.3 –8.8 0.5 –12.8
–12.0 –7.2 1.8 4.8 –13.6 –4.0 –1.3 2.3 –18.0 –7.6
S 12.9 0.8 10.1 -3.2
10.5 15.3 –4.2 5.7 7.3 12.9 –8.76 2.3
GRN PS –12.1 –2.8 –16.1
–16.6 –7.6 –4.6 –0.9 –21.3 –10.9
S 9.3 –4.0
4.7 14.0 –10.4 2.5
MAPT PS –13.3
–18.4 –.8.3
FCSRT immediate total recall
C9orf72 GRN MAPT
PS S PS S PS S
Controls –1.3 –8.7 0.7 –16.3 –2.1 14.4
–2.3 –0.3 –12.0 –5.3 0.1 1.2 –22.8 –9.8 –3.3 –0.8 –21.2 –7.5
C9orf72 PS –7.4 1.9 –15.0 –0.8 –13.1
–10.8 –4.0 0.8 3.1 –21.7 –8.4 –2.2 0.7 –20.0 –6. 1
S 9.3 –7.6 6.6 –5.7
5.9 12.7 –15.2 –0.1 3.0 10.2 –13.6 2.2
GRN PS –17.0 –2.7 –15.0
–23.5 –10.4 –4.1 –1.3 –21.9 –8.1
S 14.2 1.9
7.7 20.8 –7.1 11.0
MAPT PS –12.3
–19.2 –5.4
FCSRT delayed free recall
C9orf72 GRN MAPT
PS S PS S PS S
Controls –1.0 –5.3 0.1 –4.5 –0.9 –6.4
–1.6 –0.5 –6.3 –4.3 –0.3 0.6 –6.2 –2.8 –1.7 –0.1 –8.7 –4.0
C9orf72 PS –4.3 1.1 –3.5 0.1 –5.4
–5.4 –3.2 0.5 1.8 –5.3 –1.7 –0.8 1.0 –7.8 –3.0
S 5.5 0.8 4.4 –1.0
4.4 6.5 –1.1 2.7 3.2 5.7 –3.5 1.5
GRN PS –4.6 –1.0 –6.5
–6.3 –3.0 –1.9 –0.2 –8.9 –4.1
S 3.6 –1.9
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TABLE 2 Continued
FCSRT delayed total recall
C9orf72 GRN MAPT
PS S PS S PS S
Controls –0.3 –3.1 0.1 –4.3 –0.7 –4.5
–0.6 0.0 –4.4 –1.9 –0.1 0.4 –6.7 –1.9 –1.3 –0.2 –7.1 –1.9
C9orf72 PS –2.8 0.4 –4.0 –0.4 –4.2
–4.1 –1.5 0.1 0.8 –6.4 –1.6 –1.1 0.2 –6.8 –1.6
S –3.3 –1.2 2.4 –1.4
2.0 4.5 –3.9 1.6 1.1 3.8 –4.2 1.5
GRN PS –4.5 –0.9 –4.6
–6.8 –2.1 –1.5 –0.3 –7.2 –2.1
S 3.6 –0.2
1.1 6.1 –3.6 3.3
MAPT PS –3.8
–6.3 –1.2
Notes: Values in bold are significant at P< 0.05. Values are adjusted for age, years of education, sex, and language in which the test was administered.
Abbreviations: C9orf72, chromosome 9 open reading frame 72; FCSRT, Free and Cued Selective Reminding Test; GRN, progranulin; MAPT, microtubule-
associated protein tau; PS, presymptomatic; S, symptomatic.
F IGURE 1 Neuroanatomical correlates of performance on the FCSRT immediate free recall. Results are shown on a study-specific
T1-weightedmagnetic resonance imaging template inMontreal Neurological Institute space and at P< 0.05 family-wise error corrected. Color
bars represent T-values. Abbreviations: C9orf72, chromosome 9 open reading frame 72; FCSRT, Free and Cued Selective Reminding Test; FWE,
family-wise error;GRN, progranulin; L, left;MAPT, microtubule-associated protein tau; R, right
(Table A.4). All significant correlations were positive (i.e., lower gray
matter volume associated with worse performance).
4 DISCUSSION
This study demonstrates the presence of memory impairment in
genetic FTD, including in the presymptomatic period of MAPT and
C9orf72mutation carriers, and with differential underlying neural cor-
relates in different genetic groups. Results showed that all symp-
tomatic mutation carriers had lower performance than controls and
presymptomatic mutation carriers. Presymptomatic MAPT mutation
carriers performed lower on all four FCSRT scores compared to con-
trols, and presymptomatic C9orf72mutation carriers performed lower
than controls on all scores except delayed total recall. The strongest
associations between the FCSRT and cognitive tasks were with mea-
sures of executive function as well as memory and language in C9orf72
and GRN mutation carriers but mainly with memory and naming tests
forMAPTmutation carriers. Neural correlates varied between genetic
groups, with frontal and temporal as well as subcortical involvement
in C9orf72 andGRNmutation carriers, but almost exclusively temporal
areas being implicated in the MAPT group. Interestingly, a difference
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C9orf72 PS Immediate Free 0.14 0.12 0.28** –0.22* –0.36***
Total 0.21* 0.27** 0.30*** –0.22** –0.30***
Delayed Free 0.20* 0.22** 0.28** –0.26** –0.41***
Total 0.23** 0.23** 0.26** –0.29*** –0.27**
S Immediate Free 0.28 0.49*** 0.46** –0.21 –0.42**
Total 0.29 0.55*** 0.44** –0.24 –0.28
Delayed Free 0.46** 0.47** 0.49*** –0.25 –0.54***
Total 0.36* 0.56*** 0.54*** –0.29 –0.44**
GRN PS Immediate Free 0.27** 0.21* 0.36*** –0.31*** –0.29***
Total 0.33*** 0.26** 0.22** –0.24** –0.39***
Delayed Free 0.30*** 0.26** 0.31*** –0.42*** –0.40***
Total 0.34*** 0.21* 0.24** –0.21* –0.19*
S Immediate Free 0.52* 0.41 0.43 –0.50* 0.27
Total 0.62** 0.53** 0.57* –0.55* 0.25
Delayed Free 0.70** 0.59** 0.39 –0.58** 0.05
Total 0.45 0.57* 0.56* –0.51* –0.03
MAPT PS Immediate Free 0.40** 0.38** 0.38** –0.49*** –0.52***
Total 0.45*** 0.37** 0.36** –0.41** –0.50***
Delayed Free 0.44*** 0.38** 0.45*** –0.51*** –0.46***
Total 0.45*** 0.37** 0.25 –0.47*** –0.32*
S Immediate Free 0.74*** 0.59** 0.39 –0.30 –0.17
Total 0.70** 0.62** 0.42 –0.31 –0.22
Delayed Free 0.48 0.60** 0.35 –0.34 –0.13
Total 0.76*** 0.53* 0.20 –0.31 0.07
*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001.
Abbreviations: BNT, Boston Naming Test; C9orf72, chromosome 9 open reading frame 72; D-KEFS Color-Word, Delis–Kaplan Executive Function System
Color-Word Interference Test; FCSRT, Free and Cued Selective Reminding Test; GRN, progranulin;MAPT, microtubule-associated protein tau; PS, presymp-
tomatic; S, symptomatic; TMT-B, Trail Making Test Part B.
in frontal versus temporal involvement was seen in free versus total
recall measures in C9orf72 mutation carriers. Together these results
indicate that theFCSRT is a sensitive test in thepresymptomatic period
of C9orf72- and MAPT-associated FTD, and provides important addi-
tional insight into the underlying basis ofmemory impairment in differ-
ent forms of FTD.
All symptomatic mutation carriers had impaired memory as mea-
sured by the FCSRT compared to controls and presymptomatic
mutation carriers, whereas only MAPT- and C9orf72-associated FTD
were impaired presymptomatically. This is in line with previous studies
investigating cognitive functioning in people with genetic FTD, demon-
strating memory impairment in C9orf72-,18,22,33,34 GRN-,19,22,35 and
MAPT-22related FTD, earlier (and presymptomatically) in C9orf7236
and MAPT21,37,38 mutations, and only in the later symptomatic stages
in GRN-related FTD.17,22 Some of these studies interpreted memory
impairment as a distinctive characteristic of the specific genemutation
involved, but our results suggest that, although all (symptomatic)
genetic groupswere impaired, the underlying cause ofmemory impair-
ment might differ between the genetic groups. This is illustrated by
the finding of lower immediate free, total, and delayed free recall in
presymptomatic C9orf72 mutation carriers, while presymptomatic
MAPT carriers performed worse on all four tests, including delayed
total recall, compared to controls and presymptomatic GRN carriers.
According to the classical view, the FCSRT total scores are assumed
to represent a “true” form of memory consolidation due to the cued
format and the free recall scores are believed to bemore dependent on
executive functioning as well.5 In light of this theory, our results indi-
cate that lower performance in MAPT mutation carriers might be the
result of a purememory impairment, that starts in the presymptomatic
stage, whereas memory performance in C9orf72 mutation carriers is
initially influenced by executive dysfunction resulting in an ineffective
encoding and/or retrieval strategy. This theory is further corroborated
by our finding that in the C9orf72 group there were significant asso-
ciations between the FCSRT and executive tests such as the D-KEFS
Color-Word Interference Test in particular. In contrast, although there
were moderate associations between the FCSRT and executive tests
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F IGURE 2 Neuroanatomical correlates of performance on the FCSRT immediate total recall. Results are shown on a study-specific
T1-weightedmagnetic resonance imaging template inMontreal Neurological Institute space and at P< 0.05 family-wise error corrected. Color
bars represent T-values. C9orf72, chromosome 9 open reading frame 72; FCSRT, Free and Cued Selective Reminding Test; FWE, family-wise error;
GRN, progranulin; L, left;MAPT, microtubule-associated protein tau; R, right
in the presymptomaticMAPT group as well, the FCSRT was exclusively
associated with tests for visual and semantic memory in the symp-
tomatic group, indicating a stronger underlying temporal component
in this group. This is not surprising given that semantic impairment
has been associated with anteromedial temporal lobe atrophy and is
a common symptom in the later disease stages of people with aMAPT
mutation.22,39,40 As such, semantic impairment might also have influ-
enced performance on the FCSRT. In GRN mutation carriers, memory
processes appear to become affected at a later, symptomatic, stage of
the disease possibly due to increasing cognitive impairment in exec-
utive function or language domains affecting memory performance
as well.41 GRN mutation carriers performed better than the other
mutation carrier groups on the FCSRT in the presymptomatic stage,
whereas they performed significantly worse than C9orf72 mutation
carriers in the symptomatic stage. This is in line with previous studies
showing that there is minimal cognitive decline in presymptomatic
GRNmutation carriers, with often rapidly progressive cognitive decline
after symptom onset,21,22,35,41 whereas in C9orf72-related FTD cog-
nitive decline already starts at an early stage, and then may progress
relatively slowly for several years after symptom onset.18,22,33,34,36
Although the mean and standard deviation of FCSRT scores in the
presymptomaticMAPTmutation carriers are similar to the entire con-
trol group (Table 1), this group is significantly younger than the over-
all control group, and the adjusted mean differences seen in Table 2
approximate to the difference between the mean of the presymp-
tomatic MAPT mutation carriers and that of a younger control group
(Table A.3). For example, the mean for immediate free recall in this
group was 31.6 with a mean age within this group of 39.8, while in the
age 30 to 40 younger controls (Table A.3) the mean score was 34.0,
2.4 points higher than the presymptomaticMAPTmutation carriers.
The VBM analysis revealed that for MAPT mutation carriers both
free and total recall were correlated almost exclusively with temporal
lobe areas, including parts of the medial temporal lobe memory sys-
tem (e.g., entorhinal and parahippocampal cortices).42,43 Although this
memory network, including the hippocampus, amygdala, and fusiform
gyrus, was implicated in C9orf72 and GRN mutation carriers as well,
there was additional involvement of the frontal cortices, thalamus,
and insula in these groups, areas that are involved with executive
processes such as inhibitory control, initiative, planning of behav-
ior, and attention.44–49 Interestingly, this executive network was not
implicated in the total recall measures in C9orf72 mutation carriers
reducing it to exclusively memory-related areas. This suggests that in
C9orf72-related FTD, although frontal/executive processes influence
free recall performance, temporal/memory processes affect perfor-
mance on total recall measures. On the other hand, in GRN-related
FTD frontal/executive processes appear to influence performance on
both free and cued memory recall formats. These results are consis-
tent with previous neuroimaging studies showing progressive deterio-
ration of the brain areas that were correlated to FCSRT performance
in each genetic group.17–19,23,36,50 For example, a previous GENFI
study revealed hippocampal loss followed by temporal lobe atrophy
in presymptomatic MAPT mutation carriers from, respectively, 15 to
10yearsbeforeestimated symptomonset,whereas the insula andpari-
etal areas were the earliest affected areas in GRN and the thalamus in
C9orf72.23 Overall, the neuroanatomical correlates were more exten-
sive for the immediate than delayed recall scores. A possible explana-
tion for this might be that there is a larger variance in the distribution
of scores in immediate recall with amaximum score of 48, compared to
delayed recall with amaximum score of 16, and therefore less sensitiv-
ity to detect a change in graymatter volume.
A major strength of this study is the use of a large cohort of genetic
FTD patients and presymptomatic mutation carriers, allowing not only
gene-specific analyses, but also the use of a matched control group
of mutation-negative family members. However, despite the large
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sample size, the MAPT mutation carrier group was still smaller than
the other groups, which might have influenced particularly the power
of VBM analyses, in which we did not find significant correlations with
delayed recall test scores after FWE correction. Another limitation of
this study is that bulbar/motor symptoms of patients with FTD-ALS or
severe language difficulties in patients with PPA might have affected
performance on the FCSRT or other cognitive tests, although these
groups were in the minority compared to those with a primary diag-
nosis of bvFTD, and furthermore, instructions for test administration
include example items for most cognitive tests to check if instructions
are understood and if a patient is too severely affected the test is dis-
continued according to the judgment of an experienced neuropsychol-
ogist. Future research studies might investigate the loss of information
over the delay between the immediate and delayed recall phases; how-
ever, this data was not available in this study.
To summarize, we demonstrated significant episodic memory
impairment in genetic FTD, beginning in the presymptomatic period of
MAPT and C9orf72. Presymptomatic C9orf72 mutation carriers were
not impaired in delayed total recall (i.e., free+ cued recall), and FCSRT
free recall was more strongly associated with tests for executive func-
tioning. This suggests that lower FCSRT free recallmight initially be the
result of an ineffective retrieval strategy, rather than a “true” memory
impairment. On the other hand, presymptomatic MAPT mutation car-
riers performed, for their overall younger age, worse than controls on
both immediate and delayed total recall, with strong associations with
memory tests, suggesting that “true” memory processes affect perfor-
mance on the FCSRT in this group. In contrast, FCSRT performance
is only impaired at the symptomatic stage of GRN mutation carriers.
These findings were corroborated by demonstrating an exclusive tem-
poral/memory network association with FCSRT performance inMAPT
mutation carriers, whereas areas important for executive functioning
were also correlated with FCSRT performance in GRN and C9orf72
mutation carriers. Only temporal memory-related areas were associ-
atedwith total recall inC9orf72, suggesting that there is a purememory
component implicated in this group as well, possibly only at the symp-
tomatic stage when the temporal lobes become affected. Together,
these results demonstrate that memory deficits are an integral part of
the clinical spectrum in MAPT and C9orf72 mutation carriers. It sug-
gests that comprehensive memory tasks that can delineate executive
function and memory processes such as the FCSRT should be incorpo-
rated in the standard diagnostic work-up. In addition, they can poten-
tially serve as a useful outcomemeasure in upcoming clinical trials that
target specific pathologies.
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